Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Alexander Otto König

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0304-6242; OpenAlex author ID A5031812055. Sources: OpenAlex.

Their work

Papers
19 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
87
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 1 paper · 2014: 3 papers · 2015: 1 paper · 2016: 3 papers · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 19

  1. Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatm… Co-author DOI 10.1186/s12885-025-13573-7↗
  2. An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies. Co-author DOI 10.1053/j.gastro.2023.10.026↗
  3. A Concept for Mining Transitive Sequential Patterns from Pancreatic Cancer Patient Journeys. Co-author DOI 10.3233/shti240862↗
  4. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic canc… Co-author DOI 10.1016/j.annonc.2022.09.161↗
  5. Targeting STAT3 Signaling Facilitates Responsiveness of Pancreatic Cancer Cells to Chemoradiotherapy. Co-author DOI 10.3390/cancers14051301↗
  6. CA19-9 for detecting recurrence of pancreatic cancer. Co-author DOI 10.1038/s41598-020-57930-x↗
  7. [New milestone in adjuvant therapy for pancreatic cancer]. Co-author DOI 10.1007/s00108-019-0628-1↗
  8. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Co-author DOI 10.7150/thno.29247↗
  9. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, r… Co-author DOI 10.1186/s12885-018-5183-y↗
  10. NFATc4 Regulates Sox9 Gene Expression in Acinar Cell Plasticity and Pancreatic Cancer Initiation. Last author DOI 10.1155/2016/5272498↗
  11. GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression. Co-author DOI 10.1158/1535-7163.mct-15-0309↗
  12. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma. First author DOI 10.1159/000447739↗
  13. Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity. Co-author DOI 10.15252/embj.201489574↗
  14. Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells. Co-author DOI 10.1038/cddis.2014.102↗
  15. Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells Co-author DOI 10.1038/cddis.2014.341↗
  16. Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. Co-author DOI 10.1158/2159-8290.cd-13-0593↗
  17. SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. Co-author DOI 10.1038/oncsis.2013.23↗
  18. Mutant K-Ras increases GSK-3β gene expression via an ETS-p300 transcriptional complex in pancreatic cancer. First author DOI 10.1038/onc.2011.90↗
  19. Disruption of a nuclear NFATc2 protein stabilization loop confers breast and pancreatic cancer growth suppression by zoledronic acid. Co-author DOI 10.1074/jbc.m110.197533↗

Closest collaborators

The 25 strongest of 87 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Volker Ellenrieder · 11 shared papers, 2011–2024 · strength 0.86
  2. Elisabeth Heßmann · 6 shared papers, 2014–2024 · strength 0.50
  3. Michael B. Ghadimi · 4 shared papers, 2019–2025 · strength 0.49
  4. Thomas Theodor Werner Seufferlein · 4 shared papers, 2016–2023 · strength 0.35
  5. Ulrich Sax · 2 shared papers, 2024 · strength 0.33
  6. Christoph Ammer‐Herrmenau · 2 shared papers, 2024 · strength 0.33
  7. Daniel D. Billadeau · 8 shared papers, 2011–2016 · strength 0.31
  8. Jochen Gaedcke · 3 shared papers, 2015–2022 · strength 0.30
  9. Peter Jo · 2 shared papers, 2020–2025 · strength 0.30
  10. Günter Schneider · 2 shared papers, 2022–2024 · strength 0.29
  11. Shiv K. Singh · 5 shared papers, 2011–2024 · strength 0.27
  12. Eike Gallmeier · 3 shared papers, 2018–2023 · strength 0.25
  13. Andrea Tannapfel · 3 shared papers, 2018–2023 · strength 0.25
  14. Thomas Jens Ettrich · 3 shared papers, 2018–2023 · strength 0.25
  15. Waldemar H. Uhl · 3 shared papers, 2018–2023 · strength 0.25
  16. Michael Geißler · 3 shared papers, 2018–2023 · strength 0.25
  17. Anke Reinacher‐Schick · 3 shared papers, 2018–2023 · strength 0.25
  18. Hana Algül · 3 shared papers, 2018–2023 · strength 0.25
  19. Marko Kornmann · 3 shared papers, 2018–2023 · strength 0.25
  20. Jens Thomas Siveke · 3 shared papers, 2014–2025 · strength 0.25
  21. Albrecht Neeße · 4 shared papers, 2014–2024 · strength 0.25
  22. Jonas Hügel · 1 shared paper, 2024 · strength 0.20
  23. Marie C. Hasselluhn · 2 shared papers, 2016–2024 · strength 0.19
  24. Detlef Klaus Bartsch · 2 shared papers, 2019–2023 · strength 0.19
  25. Alexander Kleger · 2 shared papers, 2019–2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.